Latest Content

Pavlos Msaouel, MD, PhD, discusses a study of panitumumab-based EGFR blockade in SMARCB1-deficient RMC.

FDA approved generic gallium Ga 68 gozetotide injection for PET imaging of PSMA-positive lesions in prostate cancer.

The Yawkey Foundation made a $50 million grant to support Dana-Farber's planned cancer hospital and the Future of Cancer Care Fund.

Oncology experts provide commentary on the meeting's biggest and most impactful presentations across the GI cancer continuum.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

New spatial atlas of immune cell structures reveals how key features vary across tumor types and influence patient outcomes.

Lack of a statistically significant PFS improvement and improbability of achieving OS benefit led to the discontinuation of the KEYNOTE-D46/EVOKE-03 trial in PD-L1–high NSCLC.

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.

ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.

Phase 1/2 data show that the PRMT5 inhibitor vopimetostat plus daraxonrasib yielded a 92% ORR in MTAP-deleted, RAS-mutant metastatic pancreatic cancer.

City of Hope’s data-driven model integrates survivorship care from diagnosis through decades of follow-up.

Experts share the key myeloproliferative neoplasm and acute myeloid leukemia presentations they’re anticipating at the 2026 EHA Congress.

In the phase 3 RECITE trial, romiplostim significantly reduced chemotherapy dose modifications due to thrombocytopenia vs placebo in gastrointestinal cancers.